JP2023526754A5 - - Google Patents

Info

Publication number
JP2023526754A5
JP2023526754A5 JP2022563894A JP2022563894A JP2023526754A5 JP 2023526754 A5 JP2023526754 A5 JP 2023526754A5 JP 2022563894 A JP2022563894 A JP 2022563894A JP 2022563894 A JP2022563894 A JP 2022563894A JP 2023526754 A5 JP2023526754 A5 JP 2023526754A5
Authority
JP
Japan
Application number
JP2022563894A
Other languages
Japanese (ja)
Other versions
JPWO2021216385A5 (https=
JP2023526754A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/027848 external-priority patent/WO2021216385A1/en
Publication of JP2023526754A publication Critical patent/JP2023526754A/ja
Publication of JPWO2021216385A5 publication Critical patent/JPWO2021216385A5/ja
Publication of JP2023526754A5 publication Critical patent/JP2023526754A5/ja
Pending legal-status Critical Current

Links

JP2022563894A 2020-04-20 2021-04-17 Covid および covid-19 の予防と治療の方法 Pending JP2023526754A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063012432P 2020-04-20 2020-04-20
US63/012,432 2020-04-20
US202063018768P 2020-05-01 2020-05-01
US63/018,768 2020-05-01
US202063032116P 2020-05-29 2020-05-29
US63/032,116 2020-05-29
US202063037373P 2020-06-10 2020-06-10
US63/037,373 2020-06-10
US202063041812P 2020-06-19 2020-06-19
US63/041,812 2020-06-19
US202163170350P 2021-04-02 2021-04-02
US63/170,350 2021-04-02
PCT/US2021/027848 WO2021216385A1 (en) 2020-04-20 2021-04-17 Methods for the prophylaxis and treatment of covid and covid-19

Publications (3)

Publication Number Publication Date
JP2023526754A JP2023526754A (ja) 2023-06-23
JPWO2021216385A5 JPWO2021216385A5 (https=) 2024-04-30
JP2023526754A5 true JP2023526754A5 (https=) 2024-04-30

Family

ID=78270185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563894A Pending JP2023526754A (ja) 2020-04-20 2021-04-17 Covid および covid-19 の予防と治療の方法

Country Status (8)

Country Link
US (2) US12239629B2 (https=)
EP (1) EP4138906A4 (https=)
JP (1) JP2023526754A (https=)
AU (1) AU2021259185A1 (https=)
BR (1) BR112022021304A2 (https=)
CA (1) CA3179317A1 (https=)
GB (3) GB2632086A (https=)
WO (1) WO2021216385A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021216385A1 (en) 2020-04-20 2021-10-28 Tran Lloyd Hung Loi Methods for the prophylaxis and treatment of covid and covid-19
BR112022022243A2 (pt) * 2020-05-01 2022-12-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19.
JP2024538711A (ja) * 2021-10-06 2024-10-23 メディエンス カンパニー リミテッド エファビレンツ及びフルオキセチンを有効成分として含有するウイルス感染症の予防又は治療用薬学的組成物
EP4427740A4 (en) * 2021-11-05 2025-10-22 G2Gbio Inc PHARMACEUTICAL KIT FOR PARENTERAL CO-ADMINISTRATION
US20250025473A1 (en) * 2021-11-12 2025-01-23 Albert Einstein College Of Medicine Cell impermeable kinase inhibitors to treat sars-cov-2 and/or hsv viral infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002340465A1 (en) 2001-11-09 2003-05-19 Neuronz Biosciences, Inc. Cyclo(prolyl-glycine) and methods of use to treat neural disorders
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US7842719B2 (en) * 2002-10-31 2010-11-30 Kemin Foods, L.C. Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus
EP4368202A3 (en) 2007-03-30 2024-08-21 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
AU2008287542C1 (en) * 2007-06-01 2015-01-22 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
CN112423774A (zh) 2018-05-15 2021-02-26 L·H·L·特兰 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法
US10980756B1 (en) * 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
WO2021209740A1 (en) * 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
WO2021216385A1 (en) 2020-04-20 2021-10-28 Tran Lloyd Hung Loi Methods for the prophylaxis and treatment of covid and covid-19
CN111803491A (zh) * 2020-07-24 2020-10-23 中国人民解放军军事科学院军事医学研究院 青蒿素类化合物在治疗冠状病毒感染方面的应用
CN114246858A (zh) * 2020-09-21 2022-03-29 北京化工大学 青蒿素类化合物在治疗和预防冠状病毒感染中的应用

Similar Documents

Publication Publication Date Title
JP2023526754A5 (https=)
CN306215887S (https=)
CN305927040S (https=)
CN305841247S (https=)
CN305866735S (https=)
CN305867886S (https=)
CN305869466S (https=)
CN305870077S (https=)
CN305876283S (https=)
CN305880499S (https=)
CN305883333S (https=)
CN305903232S (https=)
CN305904329S (https=)
CN305905564S (https=)
CN305906813S (https=)
CN305907452S (https=)
CN305908904S (https=)
CN305912779S (https=)
CN305916101S (https=)
CN305916359S (https=)
CN305917387S (https=)
CN305917807S (https=)
CN305927580S (https=)
CN305829795S (https=)
CN305952385S (https=)